The cluster is dominated by option-exercise-related sales, which are routine and non-informational. The only pure open-market sale (Director Norwalk, $210K) is too small to signal a bearish view. No actionable trading signal here — monitor for any upcoming earnings or pipeline catalysts that could drive the stock.
Price Chart
Executive Summary
A cluster of insider selling at Neurocrine Biosciences, totaling ~$4.5M over a week, is dominated by C-suite officers exercising options and selling shares. While the dollar value is modest relative to the $16.5B market cap (~0.03%), the concentration of senior executives (CMO, CHRO, CSO, CRO) selling at similar times warrants attention, though the sales are largely tied to option exercises and tax withholding, reducing their informational signal.
Key Financial Metrics
Key Facts
- Four insiders sold shares totaling ~$4.53M in a 7-day window (May 29–June 4, 2026).
- Sales include C-suite: Chief Medical Officer, Chief Human Resources Officer, Chief Scientific Officer, and Chief Regulatory Officer.
- Total sales represent ~0.03% of NBIX's $16.5B market cap — well below the 0.1% materiality threshold.
- Most sales were preceded by option exercises (non-cash) or tied to tax withholding, suggesting liquidity-driven rather than informational selling.
- Director Norwalk Leslie V sold $210K in a standalone open-market sale — the only pure open-market sell in the cluster.
Financial Impact
Total insider sales of ~$4.53M, or ~0.03% of market cap — immaterial in absolute and relative terms.
Risk Factors
- Continued insider selling could erode confidence if it accelerates in future windows.
- No material risk identified from this cluster alone.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-NBIX-1780956502789 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | Insider Cluster | $149.50 $139.49 | ▼ −6.70% | ▼ −9.26% | $143.18 (−4.23%) |
Jul 13, 2026 11w ago | Insider Cluster | $174.10 $170.88 | ▼ −1.85% | ▼ −1.06% | $143.18 (−17.76%) |
Jul 9, 2026 12w ago | Press Release | $177.11 $171.55 | ▼ −3.14% | ▼ −2.58% | $143.18 (−19.16%) |
Jun 9, 2026 16w ago | Insider Cluster | $160.86 $156.42 | ▼ −2.76% | ▼ −6.19% | $143.18 (−10.99%) |
Jun 8, 2026 16w ago | Insider Cluster | $165.24 $159.51 | ▼ −3.47% | ▼ −5.88% | $143.18 (−13.35%) |
Jun 8, 2026 16w ago | Insider Cluster | $165.24 $159.51 | ▼ −3.47% | ▼ −5.88% | $143.18 (−13.35%) |
Jun 4, 2026 17w ago | Insider Cluster | $163.88 $159.76 | ▼ −2.51% | ▼ −3.08% | $143.18 (−12.63%) |
Jun 2, 2026 17w ago | Insider Cluster | $164.23 $160.86 | ▼ −2.05% | ▲ +1.77% | $143.18 (−12.81%) |
Jun 2, 2026 17w ago | Insider Cluster | $164.23 $160.86 | ▼ −2.05% | ▲ +1.77% | $143.18 (−12.81%) |
Jun 2, 2026 17w ago | Insider Cluster | $164.23 $160.86 | ▼ −2.05% | ▲ +1.77% | $143.18 (−12.81%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access